With Settlement In Hand, Will Teva Outstrip MSN On US Cabometyx?
Second Part Of Legal Showdown With MSN Will Shed Light On IP Landscape
Executive Summary
Teva has dealt out of US patent-infringement proceedings with Exelixis over the originator’s Cabometyx, picking up a date-certain launch early in the next decade.